KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P.
Lièvre A, et al.
Cancer Res. 2006 Apr 15;66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191.
Cancer Res. 2006.
PMID: 16618717